23 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
is governed by the national anti-bribery laws of EU member states. Infringement of these laws could result in substantial fines and imprisonment … and other worldwide anti-bribery laws, export and import controls, sanctions, embargoes, and anti-money laundering laws and regulations.
Various of our
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
or advantages to physicians is governed by the national anti-bribery laws of EU member states. Infringement of these laws could result in substantial fines … affected by violations of the FCPA and other worldwide anti-bribery laws, export and import controls, sanctions, embargoes, and anti-money laundering
8-K
EX-1.1
NAMS
NewAmsterdam Pharma Company NV
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
in the Registration Statement, the Time of Sale Prospectus or the Prospectus.
(ll) Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any … Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law
F-3
EX-1.2
NAMS
NewAmsterdam Pharma Company NV
7 Dec 23
Shelf registration (foreign)
4:16pm
required to be disclosed in the Registration Statement or the Prospectus.
(ii) Anti-Corruption and Anti-Bribery Laws. Neither the Company nor any of its … Corrupt Practices Act of 1977, as amended (the “FCPA”), the UK Bribery Act 2010, or any other applicable anti-bribery or anti-corruption law; or (iv
424B3
NAMS
NewAmsterdam Pharma Company NV
15 Aug 23
Prospectus supplement
4:52pm
by the national anti-bribery laws of EU member states. Infringement of these laws could result in substantial fines and imprisonment. Payments made to physicians … , results of operations, and financial condition.
We could be adversely affected by violations of the FCPA and other worldwide anti-bribery laws, export
POS AM
05dp4oimsrp
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
naemt
7 Aug 23
Research and development expenses
7:24am
424B3
wozk is4uge7szoz2zs
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
rz5ys1m7vpaefb
9 Jun 23
Current report (foreign)
9:39pm
424B3
6codit38n9f524xuy
8 Jun 23
Prospectus supplement
5:01pm
424B3
pka9xbmx51fpfs8voe
6 Jun 23
Prospectus supplement
4:20pm
424B3
qlxg5tx96pqmd6
25 Apr 23
Prospectus supplement
8:14am
POS AM
tmtxerml
17 Apr 23
Prospectus update (post-effective amendment)
9:09am
F-1
4z473h lqrsti
19 Dec 22
Registration statement (foreign)
6:22pm
6-K
EX-2.1
1xafajjn
23 Nov 22
Current report (foreign)
4:36pm
424B3
u3mgue
18 Oct 22
Prospectus supplement
4:41pm
F-4/A
gz8sx4d2
13 Oct 22
Registration of securities (foreign) (amended)
5:18pm
F-4/A
aw46f6pw
3 Oct 22
Registration of securities (foreign) (amended)
5:12pm
F-4/A
EX-10.9
0qhglfk
13 Sep 22
Registration of securities (foreign) (amended)
5:03pm